ACIP Dengue Vaccines Workgroup

Robert Atmar, MD
ACIP Member and Workgroup Chair
ACIP Meeting October 28, 2020
ACIP Dengue Vaccines Workgroup

**ACIP Members**
- Robert Atmar (Chair)
- Beth Bell
- Veronica McNally
- Kathy Poehling

**CDC Lead**
- Steve Waterman
- Gabriela Paz-Bailey (Co-Lead)

**Ex Officio Members**
- Kaitlyn Morabito (NIH)
- Doran Fink (FDA)
- Kirk Prutzman (FDA)
- Srihari Seshadri (DOD)

**Liaison Representatives**
- Elizabeth Barnett (AAP)
- Rob Schechter (AIM)

**Consultants**
- Edwin Asturias
- Alan Barrett
- Wilbur Chen
- Anna Durbin
- Ines Esquilin
- Tony Marfin
- Hal Margolis
- Kristen Pierce
- Anita Shet

**CDC Contributors**
- Laura Adams
- Mimi Eckert
- Rachel Eidex
- Susan Hills
- Terri Hyde
- Mike McNeil
- Jorge Munoz
- Cindy Weinbaum
Dengue Vaccines Workgroup Discussions
March 2020-October 2020

- Review of February ACIP Dengue Vaccines session and discussion of possible phased implementation of CYD-TDV in Puerto Rico
- Sanofi Pasteur CYD-TDV cost effectiveness study
- Acceptability of a CYD-TDV vaccination program for 9-16 year old children to Puerto Rico pediatricians and school officials, key informant interviews
- Overview of two economic analyses by CDC ACIP health economist
- Preliminary results of CDC Phase 1 evaluation of dengue IgG tests
- Review of initial drafts of EtR for CYD-TDV
ACIP Dengue Vaccines Workgroup Update
Phased Implementation in Puerto Rico Discussions

- Workgroup had considerable discussions about a phased approach to work out logistics and feasibility of pre-vaccination screening in Puerto Rico

- Discussions included observations that keeping an ACIP recommendation simple is desirable
  - Suggestion that MMWR background document comment that CYD-TDV vaccine poses novel challenges making phased implementation potentially helpful
  - Ultimately the territorial health department will have the responsibility on how to roll out the vaccine
ACIP Dengue Vaccines Workgroup Update
Acceptability Discussions

- CYD-TDV appears acceptable to Puerto Rico stakeholders, but further education is needed for physicians and parents on the benefits and risks

- No information on vaccine acceptability and feasibility in other U.S. territories at this time, but efforts are under way (may not be available by February 2021)
ACIP Dengue Vaccines
Cost effectiveness – Notre Dame Study

- Base scenario: Test Sp-95%, Se-80%; 50% dengue seroprevalence; vaccinating 9 yr-olds over 10 yrs (80% screened)

- 3,415 hospitalizations averted; ratio of 18.6 hospitalizations averted for each additional hospitalization (due to vaccinating a falsely seropositive child)

- Notre Dame study found ICERs for hospitalizations averted of $16,000 ($9,400 - $29,000) and QALYs of $122,000 ($74,000 - $182,000)
  - Estimated range based the uncertainty of model parameters fit to the vaccine trial data

ACIP Dengue Vaccines Workgroup Update
Pre-vaccination Laboratory Screening Test

- EtR judgments are dependent on the performance of pre-vaccination screening test for prior dengue infection

- Second phase CDC evaluation of dengue IgG assays showing good Sp and Se on early convalescent serum samples is pending (expect results before end of the year)

- With the assumption that one or more commercially available dengue IgG assays meet international target product profile for acceptable Sp and Se (95%, 85%), the expected judgment on benefits/harms will be “favors intervention”
ACIP Dengue Vaccines Workgroup Update
Anticipated Discussions

- Further Workgroup discussions to finalize the EtR incorporating the results of the dengue IgG lab test evaluation will likely focus on:
  - Health Equity
  - Feasibility in Puerto Rico and other U.S. Territories including the cost and availability of laboratory testing
  - Shared decision making versus an unqualified recommendation
  - New data in August 2020 Science paper suggesting that prior Zika infection enhances risk of severe dengue

ACIP Dengue Vaccines Workgroup

- Anticipated ACIP Schedule 2021

  - February 2021
    - CDC assessment of laboratory tests for pre-vaccination screening
    - Evidence to Recommendations Framework with draft CYD-TDV recommendations

  - June 2021
    - ACIP vote CYD-TDV recommendations
• Are there specific data ACIP would like presented?
• Are there other considerations the Work Group should address?
ACKNOWLEDGEMENTS

Laura Adams
Doug Campos-Outcalt
Andrew Leidner
Freddy Medina
Gabriela Paz-Bailey
Coral Rosado
Steve Waterman
ACIP Dengue Vaccines Work Group Members
Thank you!
Questions?

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.